Boehringer Ingelheim Pharmaceuticals has announced the permanent discontinuation of Mobic (meloxicam) Oral Suspension, 7.5mg/5mL and its authorized generic Meloxicam Oral Suspension, 7.5mg/5mL. The decision to discontinue the product is business-related and not due to product safety or efficacy.
Mobic is a non-steroidal anti-inflamatory drug (NSAID) indicated for the relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. It is also approved for the relief of the signs and symptoms of pauciarticular or polyarticular course juvenile rheumatoid arthritis in patients 2 years of age and older.
The tablet form of this product continues to be available.
For more information call (800) 542-6257 or visit FDA.gov.